NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
12/24/2024
Back to search
Official data from USPTO
KENOX PHARMACEUTICALS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
32
Latest update
12/24/2024
Classification
Registered
Trademark type
Combined
Nice classes
42
Filing date
05/31/2022
Registration date
12/24/2024
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/24/2024
Last transaction
12/24/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
10/01/2019
First use in commerce
10/01/2019
Drawing code
3
Owner type
03
Owner location
South Plainfield, NJ, US
Examiner
LEE,YATSYE ISADORA
Law office
L70
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the word "KENOX" in stylized capital letters, with the "E" represented by three parallel horizontal lines and the "O" represented by three unconnected arcs in the form of a circle, with a series of circular solid dots in a helical array both inside and outside the "O", all of the aforesaid appearing over the word "PHARMACEUTICALS" in smaller stylized capital letters.
Holders and representatives
Holders
Kenox Pharmaceuticals Inc.
Representatives
Y. Jae Kim KIM IP LAW GROUP LLC
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Research and development services in the field of pharmaceutical preparations
Publications
History of USPTO decisions and trademark events.
32 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
12/24/2024
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
10/25/2024
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
10/25/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
10/01/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
10/01/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
10/01/2024
SNEA
SU-EXAMINER'S AMENDMENT WRITTEN
10/01/2024
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
05/02/2024
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
05/02/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
02/22/2024
GNRT
NON-FINAL ACTION E-MAILED
02/22/2024
CNRT
SU - NON-FINAL ACTION - WRITTEN
02/22/2024
SUPC
STATEMENT OF USE PROCESSING COMPLETE
01/26/2024
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
01/26/2024
IUAF
USE AMENDMENT FILED
01/05/2024
EISU
TEAS STATEMENT OF USE RECEIVED
01/05/2024
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
09/05/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/11/2023
PUBO
PUBLISHED FOR OPPOSITION
07/11/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/21/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/07/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/02/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/01/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/01/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
03/16/2023
GNRT
NON-FINAL ACTION E-MAILED
03/16/2023
CNRT
NON-FINAL ACTION WRITTEN
03/16/2023
DOCK
ASSIGNED TO EXAMINER
03/16/2023
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
06/08/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/07/2022
NWAP
NEW APPLICATION ENTERED
06/03/2022
Continuous trademark protection
Get notified about every new filing that threatens KENOX PHARMACEUTICALS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.